KR20180030549A - 전립선 질병을 위한 바이오마커 조합 - Google Patents

전립선 질병을 위한 바이오마커 조합 Download PDF

Info

Publication number
KR20180030549A
KR20180030549A KR1020187002340A KR20187002340A KR20180030549A KR 20180030549 A KR20180030549 A KR 20180030549A KR 1020187002340 A KR1020187002340 A KR 1020187002340A KR 20187002340 A KR20187002340 A KR 20187002340A KR 20180030549 A KR20180030549 A KR 20180030549A
Authority
KR
South Korea
Prior art keywords
gpc
analyte
hgf
bph
cap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187002340A
Other languages
English (en)
Korean (ko)
Inventor
브래들리 월시
더글러스 캠벨
줄리 순
Original Assignee
미노믹 인터내셔널 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015902919A external-priority patent/AU2015902919A0/en
Application filed by 미노믹 인터내셔널 리미티드 filed Critical 미노믹 인터내셔널 리미티드
Publication of KR20180030549A publication Critical patent/KR20180030549A/ko
Ceased legal-status Critical Current

Links

Classifications

    • G01N33/57434—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G01N33/57484—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/342—Prostate diseases, e.g. BPH, prostatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020187002340A 2015-07-22 2016-07-22 전립선 질병을 위한 바이오마커 조합 Ceased KR20180030549A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015902919A AU2015902919A0 (en) 2015-07-22 Biomarker combinations for prostate disease
AU2015902919 2015-07-22
PCT/AU2016/000260 WO2017011855A1 (en) 2015-07-22 2016-07-22 Biomarker combinations for prostate disease

Publications (1)

Publication Number Publication Date
KR20180030549A true KR20180030549A (ko) 2018-03-23

Family

ID=57833476

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187002340A Ceased KR20180030549A (ko) 2015-07-22 2016-07-22 전립선 질병을 위한 바이오마커 조합

Country Status (8)

Country Link
US (1) US20180224454A1 (enExample)
EP (1) EP3325972B1 (enExample)
JP (1) JP6760666B2 (enExample)
KR (1) KR20180030549A (enExample)
CN (1) CN107850600A (enExample)
AU (1) AU2016297676B2 (enExample)
CA (1) CA2993102A1 (enExample)
WO (1) WO2017011855A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3003032A1 (en) * 2018-04-27 2019-10-27 Nanostics Inc. Methods of diagnosing disease using microflow cytometry
JP2020028278A (ja) * 2018-08-24 2020-02-27 国立大学法人九州大学 被検体に生じるイベントを予測するための判別器の生成方法、及び前記判別器を用いた被検体の層別化方法
WO2020069580A1 (en) * 2018-10-05 2020-04-09 Minomic International Ltd. Biomarker combinations for determining aggressive prostate cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020784A2 (en) * 2003-05-23 2005-03-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
RU2473555C2 (ru) * 2006-12-19 2013-01-27 ДжинГоу, Инк. Новые способы функционального анализа большого количества экспериментальных данных и групп генов, идентифицированных из указанных данных
KR20090115133A (ko) * 2007-02-02 2009-11-04 노파르티스 아게 골-관련 장애를 치료하기 위한 스클레로스틴 결합 파트너의 조절물질
WO2015106311A1 (en) * 2014-01-17 2015-07-23 Minomic International Ltd. Cell surface prostate cancer antigen for diagnosis

Also Published As

Publication number Publication date
JP2018520366A (ja) 2018-07-26
US20180224454A1 (en) 2018-08-09
AU2016297676A1 (en) 2018-02-01
WO2017011855A1 (en) 2017-01-26
JP6760666B2 (ja) 2020-09-23
AU2016297676B2 (en) 2022-09-01
EP3325972B1 (en) 2020-08-19
CN107850600A (zh) 2018-03-27
HK1250257A1 (en) 2018-12-07
CA2993102A1 (en) 2017-01-26
EP3325972A1 (en) 2018-05-30
EP3325972A4 (en) 2019-02-27

Similar Documents

Publication Publication Date Title
CN113439212B (zh) 用于确定侵袭性前列腺癌的生物标志物组合
EP3325972B1 (en) Biomarker combinations for prostate disease
JP7547332B2 (ja) 膀胱癌の検出
US20230305009A1 (en) Biomarker combinations for determining aggressive prostate cancer
US20230375554A1 (en) Identification and characterization of ovarian cancer specific biomarkers in vaginal secretions
EP4409291A1 (en) Detection of bladder cancer in males
HK1250257B (en) Biomarker combinations for prostate disease
US11791043B2 (en) Methods of prognosing early stage breast lesions
US20240345092A1 (en) Risk prediction model for prostate cancer
WO2024082026A1 (en) Methods for detecting aggressive prostate cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000